Get the Stockscreener App
6.54
10.90%
-0.80
After Hours:
6.51
-0.03
-0.46%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $6.54, with a volume of 3.31M.
It is down -10.90% in the last 24 hours and down -16.15% over the past month.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$7.34
Open:
$7.3
24h Volume:
3.31M
Relative Volume:
1.63
Market Cap:
$2.41B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-13.62
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
-12.33%
1M Performance:
-16.15%
6M Performance:
+21.34%
1Y Performance:
-19.56%
1-Day Range:
$6.54
$7.33
1-Week Range:
$6.54
$7.53
52-Week Range:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.54 | 2.41B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Jefferies cuts Bausch Health stock rating to hold, target to $8 - MSN
Bausch Health cut to hold by Jefferies over B+L update (BHC:NYSE) - Seeking Alpha
Bausch Health Companies Inc. - Baystreet.ca
Bausch + Lomb won’t sell after engaging with potential buyers - Mass Device
Bausch + Lomb ends sale process, to focus on 2025 plans - MSN
Contact lens maker Bausch + Lomb rules out going private at this time - Yahoo Canada Finance
Bausch Health Retains Bausch + Lomb, Explores New Financial Strategies - TipRanks
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Yahoo Finance Australia
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal -February 06, 2025 at 07:27 am EST - Marketscreener.com
Bausch Health Provides Update on Strategic Alternatives - ACCESS Newswire
Private Equity Buyout Rejected: Inside Bausch Health's Strategic Decision on Bausch + Lomb - StockTitan
Bausch + Lomb Privatization Deal Falls Through: Revenue Growth Still on Track - StockTitan
Private Management Group Inc. Cuts Position in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Keratoconus Treatment Market reached US$ 0.5 billion in 2022 - openPR
Oral Mucositis Market Growth with Trends, Analysis by Regions, - openPR
Proton Pump Inhibitors (PPIs) Market to Grow by USD 819.5 Million (2025-2029) with Drug Reformulation Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Royal Bank of Canada Issues Pessimistic Forecast for Bausch Health Companies (NYSE:BHC) Stock Price - MarketBeat
Bausch Health Companies (NYSE:BHC) Shares Down 5.2%What's Next? - MarketBeat
BofA Adjusts Price Target on Bausch Health Companies to $7 From $6 -February 03, 2025 at 10:25 am EST - Marketscreener.com
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - Yahoo Finance
RBC Previews Bausch Health Q4 -January 30, 2025 at 12:41 pm EST - Marketscreener.com
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says - Marketscreener.com
Posterior Segment Eye Disorders Market Overall Study Report - openPR
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - GlobeNewswire
Merit Financial Group LLC Makes New $228,000 Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration - ACCESS Newswire
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock - MSN
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 - ACCESS Newswire
Bausch Health Companies (BHC) Stock Forecast and Price Target 2025 - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for TSE:BHC - Defense World
Research Analysts Issue Forecasts for BHC FY2025 Earnings - Defense World
Stocks In Play: Bausch Health Companies Inc. By Baystreet.ca - Investing.com Canada
What is Zacks Research's Forecast for BHC FY2025 Earnings? - MarketBeat
Zacks Research Has Negative View of TSE:BHC FY2025 Earnings - MarketBeat
SG Americas Securities LLC Boosts Stake in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Bausch Health Announces Q4 2024 Earnings Call Date, Full Year Results Coming February 19 - StockTitan
Shareholders in Bausch Health Companies (NYSE:BHC) are in the red if they invested five years ago - Simply Wall St
Zacks Research Issues Positive Estimate for BHC Earnings - Defense World
Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks - BNN Bloomberg
Nanotechnology Drug Delivery Market Expected To Reach USD - GlobeNewswire
Nanotechnology Drug Delivery Market Expected To Reach USD 213.2 Billion by 2032, with a CAGR of 9.3% | AstraZeneca, Sanofi, Bausch Health Companies Inc. - Yahoo Finance
Zacks Research Has Positive Forecast for BHC Q1 Earnings - MarketBeat
What is Zacks Research's Estimate for TSE:BHC Q1 Earnings? - MarketBeat
International team acts for Bausch Health Companies Inc. in a US$2bn cross-border senior notes financing - Norton Rose Fulbright
Intraocular Lens Market Detailed In New Research Report 2025 | - openPR
Xifaxan selected for CMS drug price talks in 2027 - MSN
Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) PT at $7.75 - Defense World
Bausch Health Companies (NYSE:BHC) Sees Strong Trading VolumeHere's Why - MarketBeat
Xifaxan selected for CMS drug price talks in 2027 By Investing.com - Investing.com Nigeria
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):